Prescient Therapeutics has raised $6 million from shareholders and investors. The money will fund its lead cancer drug through a December dosing review and into the next stage of clinical development.

Seven Australian startups will share $15.6 million to speed up the development of new treatments, diagnostic tools and technologies for dementia and cognitive decline.

Perth company Patrys has started in-human testing of its intravenous version of the antipsychotic quetiapine. The first healthy volunteers have now been dosed in a Phase 1a trial of the drug, known as RLS-2202.

BCAL Diagnostics has started a phased rollout of Avantect Multi-Cancer in Sydney and Melbourne and plans to expand nationally later.

The Australian nuclear medicine company has agreed to lead a merger with ITM Isotope Technologies Munich SE, paying US$1.65 billion upfront on a cash-free, debt-free basis for a German company that supplies the raw material the entire targeted radionuclide therapy industry depends on.

Genetic Signatures and Microba Life Sciences have agreed on the principal commercial terms of a merger that would combine two ASX-listed Australian diagnostics businesses into a single group.

Managing Director and Chief Executive James Bonnar said, "This capital raise marks a pivotal moment for Nyrada. The strong support from both new and existing investors is a powerful validation of our science, our team, our novel drug Xolatryp, and our potential to address serious unmet clinical needs."

Anthropic has expanded its AI for Science commitment in Australia with an additional $10 million in Claude API credit grants, bringing its total investment in Australian research to $13 million since the program launched in April.

A Melbourne biotechnology company betting on immune cell cargo as a treatment for Alzheimer's disease has enlisted one of Australia's best-known stem cell laboratories to find out whether the idea holds up in human brain tissue.

Paradigm Biopharmaceuticals has appointed a new Chief Medical Officer as its osteoarthritis program moves from recruitment into a potential regulatory submission.

Cambium Bio has secured a $10.85 million funding package for the pivotal Phase 3 trial of its dry eye treatment Elate Ocular.

Hydrix has landed a multi-year contract with the National Heart Centre Singapore, giving the ASX-listed technology group a foothold in one of Asia's most prominent cardiac hospitals and a reference customer it hopes will open doors across the region.

Patrys has assembled an international panel of critical care specialists to steer the development of RLS-2202, its injectable formulation of quetiapine for delirium in acute-care settings.

Tetratherix has reported early animal results for a cataract surgery gel that it says can be left in the eye without triggering the pressure spike, the most common early complication of the procedure.

AusBiotech has welcomed concessions to changes to the R&D Tax Incentive and Capital Gains Tax but remains concerned about the potential impact on emerging life sciences companies.

Telix Pharmaceuticals has secured landmark approval from the United States Food and Drug Administration for Pixclara, making it the first FDA-sanctioned imaging agent for glioma, the most common form of brain cancer.

Radiopharm Theranostics has reported encouraging early results from a Phase 1 imaging trial of its experimental agent RAD301 in patients with pancreatic ductal adenocarcinoma, one of the most lethal and hardest-to-treat forms of cancer.

A hospital in Madrid has reached a notable milestone for OncoSil Medical, with the Australian medical device company confirming that its device has now treated its 100th patient in Spain.